C1 domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cells

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Talman, Virpi ^a   Tuominen, Raimo K ^a   af Gennäs, Gustav Boije ^a   Yli Kauhaluoma, Jari ^a   Ekokoski, Elina ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; DIACYLGLYCEROL; HMI 1A3; HMI 1B1; HMI 1B10; HMI 1B11; HMI 1B2; HMI 1B20; HMI 24A; HMP 27; NI 15E; PHORBOL 13 ACETATE 12 MYRISTATE; PHTHALIC ACID DERIVATIVE; PROTEIN KINASE C; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ISOPHTHALATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL ELONGATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HELA CELL; HUMAN; HUMAN CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; CELL CYCLE; CELL SHAPE; CELL SURVIVAL; CHEMISTRY; METABOLISM; PROTEIN TERTIARY STRUCTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; CYCLIN A; CYCLIN B1; CYCLIN D1; DIGLYCERIDES; HELA CELLS; HUMANS; PHTHALIC ACIDS; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY; RETINOBLASTOMA PROTEIN;

EID: 79956341731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020053     Document Type: Article

References (40)

1. Newton AC, (2001) Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101: 2353-2364.
2. Nishizuka Y, (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614.
3. Nishizuka Y, (1984) The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308: 693-698.
4. Griner EM, Kazanietz MG, (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7: 281-294.
5. Hofmann J, (2004) Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4: 125-146.
6. Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D, (2008) PKC isozymes in chronic cardiac disease: Possible therapeutic targets? Annu Rev Pharmacol Toxicol 48: 569-599.
7. Geraldes P, King GL, (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106: 1319-1331.
8. Sun MK, Alkon DL, (2010) Pharmacology of protein kinase C activators: Cognition-enhancing and antidementic therapeutics. Pharmacol Ther 127: 66-77.
9. Choi SH, Czifra G, Kedei N, Lewin NE, Lazar J, et al. (2008) Characterization of the interaction of phorbol esters with the C1 domain of MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase) alpha/beta. J Biol Chem 283: 10543-10549.
10. Colon-Gonzalez F, Kazanietz MG, (2006) C1 domains exposed: From diacylglycerol binding to protein-protein interactions. Biochim Biophys Acta 1761: 827-837.
11. Blumberg PM, Kedei N, Lewin NE, Yang D, Czifra G, et al. (2008) Wealth of opportunity- the C1 domain as a target for drug development. Curr Drug Targets 9: 641-652.
12. Boije af Gennäs G, Talman V, Yli-Kauhaluoma J, Tuominen RK, Ekokoski E, (2011) Current status and future prospects of C1 domain ligands as drug candidates. Curr Top Med Chem In press.
13. Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, et al. (2009) Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem 9: 498-509.
14. Boije af Gennäs G, Talman V, Aitio O, Ekokoski E, Finel M, et al. (2009) Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem 52: 3969-3981.
15. Cameron AJ, Parker PJ, (2010) Protein kinase C- A family of protein kinases, allosteric effectors or both? Adv Enzyme Regul 50: 169-77.
16. Cameron AJ, Procyk KJ, Leitges M, Parker PJ, (2008) PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer 123: 769-779.
17. Zeidman R, Lofgren B, Pahlman S, Larsson C, (1999) PKCepsilon, via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells. J Cell Biol 145: 713-726.
18. Ling M, Troller U, Zeidman R, Stensman H, Schultz A, et al. (2005) Identification of conserved amino acids N-terminal of the PKC epsilon C1b domain crucial for protein kinase C epsilon-mediated induction of neurite outgrowth. J Biol Chem 280: 17910-17919.
19. Kazanietz MG, (2005) Targeting protein kinase C and "non-kinase" phorbol ester receptors: Emerging concepts and therapeutic implications. Biochim Biophys Acta 1754: 296-304.
20. Basu A, Lazo JS, (1992) Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res 52: 3119-3124.
21. Kim H, Yoon SC, Lee TY, Jeong D, (2009) Discriminative cytotoxicity assessment based on various cellular damages. Toxicol Lett 184: 13-17.
22. Tait SW, Green DR, (2008) Caspase-independent cell death: Leaving the set without the final cut. Oncogene 27: 6452-6461.
23. McCarthy NJ, Whyte MK, Gilbert CS, Evan GI, (1997) Inhibition of ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the bcl-2 homologue bak. J Cell Biol 136: 215-227.
24. Sievers C, Billig G, Gottschalk K, Rudel T, (2010) Prohibitins are required for cancer cell proliferation and adhesion. PLoS ONE 5: e12735.
25. Mishra S, Ande SR, Nyomba BL, (2010) The role of prohibitin in cell signaling. FEBS J 277: 3937-3946.
26. Martinez-Ramos I, Maya-Mendoza A, Gariglio P, Aranda-Anzaldo A, (2005) A global but stable change in HeLa cell morphology induces reorganization of DNA structural loop domains within the cell nucleus. J Cell Biochem 96: 79-88.
27. Leung T, Chen XQ, Tan I, Manser E, Lim L, (1998) Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization. Mol Cell Biol 18: 130-140.
28. Toker A, (2005) The biology and biochemistry of diacylglycerol signalling. meeting on molecular advances in diacylglycerol signalling. EMBO Rep 6: 310-314.
29. Gould CM, Newton AC, (2008) The life and death of protein kinase C. Curr Drug Targets 9: 614-625.
30. Szallasi Z, Smith CB, Pettit GR, Blumberg PM, (1994) Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem 269: 2118-2124.
31. Blomen VA, Boonstra J, (2007) Cell fate determination during G1 phase progression. Cell Mol Life Sci 64: 3084-3104.
32. Sherr CJ, (1996) Cancer cell cycles. Science 274: 1672-1677.
33. Du W, Wu J, Walsh EM, Zhang Y, Chen CY, et al. (2009) Nutlin-3 affects expression and function of retinoblastoma protein: Role of retinoblastoma protein in cellular response to nutlin-3. J Biol Chem 284: 26315-26321.
34. Kim YT, Zhao M, (2005) Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 46: 597-613.
35. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M, (2001) Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci U S A 98: 1218-1223.
36. Khan TK, Nelson TJ, Verma VA, Wender PA, Alkon DL, (2009) A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses abeta-induced biomarker abnormality on cultured fibroblasts. Neurobiol Dis 34: 332-339.
37. Kozikowski AP, Wang S, Ma D, Yao J, Ahmad S, et al. (1997) Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. J Med Chem 40: 1316-1326.
38. Duan D, Sigano DM, Kelley JA, Lai CC, Lewin NE, et al. (2008) Conformationally constrained analogues of diacylglycerol. 29. cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities. J Med Chem 51: 5198-5220.
39. Truman JP, Rotenberg SA, Kang JH, Lerman G, Fuks Z, et al. (2009) PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo. Cancer Biol Ther 8: 54-63.
40. Kortmansky J, Schwartz GK, (2003) Bryostatin-1: A novel PKC inhibitor in clinical development. Cancer Invest 21: 924-936.